Machín GL, Alcantar SJL, Gille L, Monzote FL

Language: Spanish
References: 29
Page: 1-16
PDF size: 601.06 Kb.

ABSTRACT

Introduction: Leishmaniasis parasitosis caused by species of protozoa of the genus Leishmania is a health problem of worldwide incidence included in the list of neglected tropical diseases. The use of conventional drugs is limited by their high cost, development of resistance and occurrence of adverse effects. Previous studies demonstrated the efficacy of intralesional ascaridole in experimental cutaneous leishmaniasis in BALB/c mice and recommended further evaluation of in vivo antileishmanial properties of this endoperoxide.
Objective: To evaluate the potentialities of ascaridole in two models of experimental cutaneous leishmaniasis based on BALB/c (susceptible) and C57BL/6 (resistant) mice.
Methods: Weight variation, lesion size evolution and parasite load were measured in BALB/c and C57BL/6 mice infected with L. amazonensis and treated orally or intralesionally, with five 30 mg/kg treatments every four days.
Results: In both models, animals treated with ascaridole showed smaller lesion sizes and parasite load than the untreated infected group (p < 0.05) and comparable to Glucantime (p > 0.05), the reference drug. In the model C57BL/6 - L. amazonensis, the ability of ascaridole to control the development of the disease after intralesional administration was highlighted.
Conclusions: The in vivo potentialities of ascaridole on L. amazonensis are demonstrated. It is recommended to explore this drug in the design of new drugs for the treatment of cutaneous leishmaniasis.

REFERENCES

1. Fudickar W, Linker T. Release of singlet oxygen from aromatic endoperoxides by chemicaltriggers. Angew Chem Int. 2018;57(39):12971-5. DOI: 10. 1002/anie. 201806881.

2. Dembitsky VM, Ermolenko E, Savidov N, Gloriozova TA, Poroikov VV. Antiprotozoal andantitumor activity of natural polycyclic endoperoxides: origin, structures and biologicalactivity. Molecules. 2021;26(3):686. DOI: 10. 3390/molecules26030686.

3. Lainson R, Shaw JJ. Evolution, classification and geographical distribution. Theleishmaniases in biology and medicine. Biology and epidemiology Academic Press. London. 1987 [acceso 05/01/2022];(1):1-120. Disponible en: https://patua. iec. gov. br/handle/iec/2715

4. Reimão JQ, Coser EM, Lee MR, Coelho AC. Laboratory diagnosis of cutaneous and visceralleishmaniasis: current and future methods. Microorg. 2020;8(11):1632. DOI:10. 3390/microorganisms8111632.

5. Volpedo G, Huston R, Holcomb E, Pacheco T, Gannavaram S, Bhattacharya P, et al. Frominfection to vaccination: reviewing the global burden, history of vaccine development, andrecurring challenges in global leishmaniasis protection. Expert Rev Vaccines. 2021;20(11):1431-46. DOI: 10. 1080/14760584. 2021. 1969231.

6. Pacheco-Fernandez T, Volpedo G, Gannavaram S, Bhattacharya P, Dey R, Satoskar A, etal. Revival of Leishmanization and Leishmanin. Front Cell Infect Microbiol. 2021;11:639801. DOI: 10. 3389/fcimb. 2021. 639801.

7. Olías AI, de la Fuente C, Cuquerella M, Torrado JJ, Alunda JM. Antileishmanial drugdiscovery and development: Time to reset the model? Microorganisms. 2021;9(12):2500. DOI:10. 3390/microorganisms9122500.

8. Daga MK, Rohatgi I, Mishra R. Leishmaniasis. Indian J Crit Care Med. 2021;25(2):166-70. DOI: 10. 5005/jp-journals-10071-23844.

9. Monzote L, García M, Pastor J, Gille L, Scull R, Maes L, et al. Essential oil fromChenopodium ambrosioides and main components: activity against Leishmania, theirmitochondria and other microorganisms. Exp Parasitol. 2013;136:20-6. DOI:10. 1016/j. exppara. 2013. 10. 007.

10. Monzote L, García M, Scull R, Cuellar A, Setzer WN. Antileishmanial activity of theessential oil from Bixa orellana. Phytother Res. 2014;28(5):753-8. DOI: 10. 1002/ptr. 5055.

11. Geroldinger G, Tonner M, Hettegger H, Bacher M, Monzote L, Walter M, et al. Mechanismof ascaridole activation in Leishmania. Biochem Pharmacol. 2017;132:48-62. DOI:10. 1016/j. bcp. 2017. 02. 023.

12. Bhattacharya A, Corbeil A, do Monte R, Fernandez C. Of drugs and trypanosomatids: Newtools and knowledge to reduce bottlenecks in drug discovery. Genes (Basel). 2020;11(7):722. DOI: 10. 3390/genes11070722.

13. Probst CM, Silva RA, Menezes JP, Almeida TF, Gomes IN, Dallabona AC, et al. Acomparison of two distinct murine macrophage gene expression profiles in response toLeishmania amazonensis infection. BMC Microbiol. 2012;12:22. DOI: 10. 1186/1471-2180-12-22.

14. Buffet P, Sulahian A, Garin Y, Nassar N, Derouin F. Culture microtitration: a sensitivemethod for quantifying Leishmania infantum in tissues of infected mice. Antimicrob AgentsChemother. 1995;39(9):2167-8. DOI: 10. 1128/aac. 39. 9. 2167.

15. Hong A, Andrade R, Jon J, Maria L, Laranjeira-Silva F. One health approach toleishmaniases: understanding the disease dynamics through diagnostic tools. Pathogens. 2020;9(10):809. DOI: 10. 3390/pathogens9100809.

16. Caridhna D, Vesely B, Van Bocxlaer K, Arana B, Mowbray C, Rafati S, et al. Route mapfor the discovery and pre-clinical development of new drugs and treatments for cutaneousleishmaniasis. IJP: Drug Drug Resist. 2019;11:106-17. DOI 10. 1016/j. ijpddr. 2019. 06. 003.

17. Serbate Á, Margotto C, da Silva MF, Silva SA, Moreira AM, Parreiras MA. Adversereactions to meglumine antimoniate in Brazilian inpatients with visceral leishmaniases: A caseseries. J Clin Pharm Ther. 2020;45(3):573-6. DOI: 10. 1111/jcpt. 13089.

18. Restrepo CM, Llanes A, Herrera L, Ellis E, Lleonart R, Fernández PL. Gene expressionpatterns associated with Leishmania panamensis infection in macrophages from BALB/c andC57BL/6 mice. PLoS Negl Trop Dis. 2021;15(2):e0009225. DOI:10. 1371/journal. pntd. 0009225.

19. Lipoldová M, Demant P. Genetic susceptibility to infectious disease: lessons from mousemodels of leishmaniasis. Nat Rev Genet. 2006;7(4):294-305. DOI: 10. 1038/nrg1832.

20. Herrera L, Llanes A, Alvarez J, Degracia K, Restrepo CM, Rivera R, et al. Antileishmanialactivity of a new chloroquine analog in an animal model of Leishmania panamensis infection. Int J Parasitol Drugs Drug Resis. 2020;14:56-61. DOI: 10. 1016/j. ijpddr. 2020. 08. 002.

21. Velasquez L, Galuppo M, Rezende E, Brandão W, Peron JP, Uliana S, et al. Distinctcourses of infection with Leishmania (L. ) amazonensis are observed in BALB/c, BALB/c nudeand C57BL/6 mice. Parasitol. 2016;143(6):692-703. DOI: 10. 1017/S003118201600024X.

22. Machín L, Nápoles R, Gille L, Monzote L. Leishmania amazonensis response toartemisinin and derivatives. Parasitol Int. 2021;80:102218. DOI: 10. 1016/j. parint. 2020. 102218

23. Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Dis TodayTechnol. 2004;4(1):337-41. DOI: 10. 1016/j. ddtec. 2004. 11. 007.

24. Monzote L, García M, Montalvo AM, Linares R, Scull R. Effect of oral treatment with theessential oil from Chenopodium ambrosioides against cutaneous leishmaniasis in BALB/cmice, caused by Leishmania amazonensis. Forsch Komplementmed. 2009;16(5):334-8. DOI:10. 1159/000237741.

25. Monzote L, Montalvo AM, Scull R, Miranda M, Abreu J. Activity, toxicity and analysis ofresistance of essential oil from Chenopodium ambrosioides after intraperitoneal, oral andintralesional administration in BALB/c mice infected with Leishmania amazonensis: apreliminary study. Biomed Pharmacother. 2007;61(2-3):148-53. DOI:10. 1016/j. biopha. 2006. 12. 001.

26. Briones CA, Cid A, Romero AI, García MF, Villegas M, Bermúdez JM. An appraisal ofthe scientific current situation and new perspectives in the treatment of cutaneousleishmaniasis. Acta Trop. 2021;221:105988. DOI: 10. 1016/j. actatropica. 2021. 105988.

27. Awasthi A, Mathur RK, Saha B. Immune response to Leishmania infection. Indian J MedRes. 2004 [acceso 01/02/2022];119(6):238-58. Disponible en:https://pubmed. ncbi. nlm. nih. gov/15243162/

28. Mears ER, Modabber F, Don R, Johnson GE. A review: The current in vivo models for thediscovery and utility of new anti-leishmanial drugs targeting cutaneous leishmaniasis. PLoSNegl Trop Dis. 2015;9(9):e0003889. DOI: 10. 1371/journal. pntd. 0003889.

29. Ide J, Hong A, Andrade R, Floeter LM, Laranjeira MF. In vivo infection with Leishmaniaamazonensis to evaluate parasite virulence in mice. J Vis Exp. 2020;156. DOI: 10. 3791/60617.